CAMBRIDGE, Mass., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma, Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced that Oliver S. Fetzer, Ph.D., President and Chief Executive Officer, will present at the following conferences:
- Wedbush Securities Life Sciences Management Access Conference in New York City on Wednesday, August 13, 2014, at 3:05 p.m. ET
- Canaccord Genuity 34th Annual Growth Conference in Boston on Thursday, August 14, 2014, at 11:00 a.m. ET
A live webcast of each presentation will be available in the investors section of the Company's website: www.ceruleanrx.com. A replay of each presentation will be available approximately two hours after the event and will be available for two weeks following that presentation.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. www.ceruleanrx.com